| Source: |
| Type: measurement |
| Bioavailability (usually in %) absorbed by the body. |
| 8645- | MBZ, | HPMA Copolymer Mebendazole Conjugate Allows Systemic Administration and Possesses Antitumour Activity In Vivo |
| - | vitro+vivo, | Colon, | CT26 |
| 8648- | MBZ, | Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature |
| - | Review, | Var, | NA |
| 8646- | MBZ, | Extensive improvement of oral bioavailability of mebendazole, a brick dust, by polymer-containing SNEDDS preparation: Disruption of high crystallinity by utilizing its counter ion |
| - | in-vivo, | Var, | NA |
| 8812- | MCP, | Investigation of Antitumor Activity of Modified Citrus Pectin: Oral and Intravenous Administration Assessed via Molecular Imaging |
| - | vitro+vivo, | Ovarian, | SKOV3 | - | in-vitro, | GC, | MKN-28 | - | in-vitro, | BC, | 4T1 |
| 8620- | MCT, | Medium-Chain Triglycerides: Scientific and Regulatory Perspectives from Germany and Japan with a US Context—A Concise Review |
| - | Review, | Nor, | NA |
| 6541- | MeSal, | Toxicology Answer: Oil of Wintergreen |
| - | Review, | Nor, | NA |
| 6537- | MeSal, | The ancient drug salicylate directly activates AMP-activated protein kinase |
| - | Review, | Nor, | NA |
| 8707- | MET, | Metformin in therapeutic applications in human diseases: its mechanism of action and clinical study |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 8708- | MET, | Tumour, whole-blood, plasma and tissue concentrations of metformin in lung cancer patients |
| - | Human, | Lung, | NA |
| 5795- | MET, | Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | Diabetic, | NA |
| 2250- | MF, | MNPs, | Confronting stem cells with surface-modified magnetic nanoparticles and low-frequency pulsed electromagnetic field |
| - | Review, | Var, | NA |
| 3468- | MF, | An integrative review of pulsed electromagnetic field therapy (PEMF) and wound healing |
| - | Review, | Nor, | NA |
| 8462- | Mg, | Mg citrate found more bioavailable than other Mg preparations in a randomised, double-blind study |
| - | Trial, | Nor, | NA |
| 782- | Mg, | Oral magnesium supplements for cancer treatment‐induced hypomagnesemia: Results from a pilot randomized trial |
| - | Trial, | Var, | NA |
| 9160- | MG, MIC-1, | Moringa isothiocyanate-1 is bioaccessible and bioavailable as a stable unmodified compound |
| - | Review, | Nor, | NA |
| 9076- | MGF, | Pharmacokinetic study of mangiferin in human plasma after oral administration |
| - | Study, | Nor, | NA |
| 9087- | MGF, | Mangiferin in human disease: Multifaceted mechanisms and applications (Review) |
| - | Review, | Var, | NA |
| 9090- | MGF, | Evaluation of the intestinal transmembrane transport and absorption characteristics of mangiferin in rats by the Ussing chamber technique |
| - | in-vivo, | Nor, | NA |
| 1782- | MLT, | Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities |
| - | Review, | Var, | NA |
| 8673- | MLT, | Therapeutic Potential of Melatonin in Gastrointestinal Cancers: Molecular Mechanisms, Preclinical Evidence and Clinical Implications |
| - | Review, | GC, | NA |
| 8683- | MLT, | Intra-tumor ROS amplification by melatonin interferes in the apoptosis-autophagy-inflammation-EMT collusion in the breast tumor microenvironment |
| - | in-vivo, | BC, | NA |
| 656- | MNPs, | MF, | Effects of combined delivery of extremely low frequency electromagnetic field and magnetic Fe3O4 nanoparticles on hepatic cell lines |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | Nor, | HL7702 |
| 8901- | MOR, | Preparation, characterization, and in vivo evaluation of a self-nanoemulsifying drug delivery system (SNEDDS) loaded with morin-phospholipid complex |
| - | in-vivo, | Nor, | NA |
| 8902- | MOR, | Enhanced oral bioavailability of morin administered in mixed micelle formulation with PluronicF127 and Tween80 in rats |
| - | vitro+vivo, | Nor, | NA |
| 8903- | MOR, | QC, | Profound difference in pharmacokinetics between morin and its isomer quercetin in rats |
| - | in-vivo, | Nor, | NA |
| 8874- | MOR, | The anticarcinogenic and anticancer effects of the dietary flavonoid, morin: Current status, challenges, and future perspectives |
| - | Review, | Var, | NA |
| 8894- | MOR, | Development of morin/hydroxypropyl-β-cyclodextrin inclusion complex: Enhancement of bioavailability, antihyperalgesic and anti-inflammatory effects |
| - | in-vivo, | Nor, | NA |
| 8889- | MOR, | Selected Flavonols in Breast and Gynecological Cancer: A Systematic Review |
| - | Review, | BC, | NA | - | Review, | Ovarian, | NA |
| 8888- | MOR, | Morin improves learning and memory in healthy adult mice |
| - | in-vivo, | AD, | NA |
| 8858- | MOR, | Mechanisms of poor oral bioavailability of flavonoid Morin in rats: From physicochemical to biopharmaceutical evaluations |
| - | in-vivo, | Nor, | NA |
| 8877- | MOR, | Enhancing bioavailability of morin via multi-particulate dosage forms: Development and pharmacokinetic insights |
| - | in-vivo, | Nor, | NA |
| 8950- | mushLions, | Absolute Bioavailability, Tissue Distribution, and Excretion of Erinacine S in Hericium erinaceus Mycelia |
| - | in-vivo, | AD, | NA |
| 8964- | mushLions, | Lion’s Mane Mushroom (Hericium erinaceus): A Neuroprotective Fungus with Antioxidant, Anti-Inflammatory, and Antimicrobial Potential—A Narrative Review |
| - | Review, | Nor, | NA | - | Review, | AD, | NA |
| 9312- | MushMait, | Mushroom-derived polysaccharides in cancer immunotherapy: mechanisms, human evidence, and translational priorities |
| - | Review, | Var, | NA |
| 2933- | NAD, | Nicotinamide mononucleotide (NMN) as an anti-aging health product – Promises and safety concerns |
| - | Review, | Nor, | NA | - | NA, | AD, | NA | - | NA, | Diabetic, | NA | - | NA, | Stroke, | NA | - | NA, | LiverDam, | NA | - | NA, | Park, | NA |
| 2936- | NAD, | The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update |
| - | Review, | Nor, | NA |
| 5620- | NaHCO3, | Tumor acidity: From hallmark of cancer to target of treatment |
| - | Review, | Var, | NA |
| 1798- | NarG, | Naringenin: A potential flavonoid phytochemical for cancer therapy |
| - | Review, | Var, | NA |
| 1799- | NarG, | Naringenin as potent anticancer phytocompound in breast carcinoma: from mechanistic approach to nanoformulations based therapeutics |
| - | Review, | BC, | NA |
| 1804- | NarG, | Beneficial effects of citrus flavanones naringin and naringenin and their food sources on lipid metabolism: An update on bioavailability, pharmacokinetics, and mechanisms |
| - | Review, | Nor, | NA |
| 1805- | NarG, | Naringenin suppresses epithelial ovarian cancer by inhibiting proliferation and modulating gut microbiota |
| - | in-vitro, | Ovarian, | A2780S | - | in-vivo, | NA, | NA |
| 1806- | NarG, | Naringin: Nanotechnological Strategies for Potential Pharmaceutical Applications |
| - | Review, | Var, | NA |
| 5253- | NCL, | Niclosamide: Beyond an antihelminthic drug |
| - | Review, | Var, | NA |
| 5254- | NCL, | The magic bullet: Niclosamide |
| - | Review, | Var, | NA |
| - | Trial, | Nor, | NA |
| 4643- | OLE, | HT, | Use of Oleuropein and Hydroxytyrosol for Cancer Prevention and Treatment: Considerations about How Bioavailability and Metabolism Impact Their Adoption in Clinical Routine |
| - | Review, | Var, | NA |
| 4631- | OLE, | Evidence to Support the Anti-Cancer Effect of Olive Leaf Extract and Future Directions |
| - | Review, | Var, | NA |
| 4646- | OLEC, | Oleocanthal as a Multifunctional Anti-Cancer Agent: Mechanistic Insights, Advanced Delivery Strategies, and Synergies for Precision Oncology |
| - | Review, | Var, | NA |
| 1814- | Oxy, | Hyperbaric oxygen therapy for malignancy: a review |
| - | Review, | Var, | NA |
| 9045- | PatchO, | Patchouli alcohol triggers autophagic cell death in non-small cell lung cancer cells through targeting GNAI1 to dissociate the GNAI1/ARRB1 complex |
| - | vitro+vivo, | NSCLC, | H1299 | - | in-vitro, | Lung, | A549 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:792 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid